H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Centogene NV (CNTG – Research Report) today and set a price target of $2.50. The company’s shares closed yesterday at $1.12.
According to TipRanks, Chen is an analyst with an average return of -15.8% and a 31.90% success rate. Chen covers the Healthcare sector, focusing on stocks such as CareDx, Prophase Labs, and Applied DNA Sciences.
Currently, the analyst consensus on Centogene NV is a Moderate Buy with an average price target of $2.50.
See the top stocks recommended by analysts >>
CNTG market cap is currently $23.7M and has a P/E ratio of -0.40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.
Read More on CNTG:
- In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)
- Centogene regains compliance with Nasdaq listing requirements
- CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day
- Twist Centogene launch target enrichment panels for rare disease diagnosis
- Centogene, Denali extend observational study on Parkinson’s disease genetics
